Free Trial

Stryker (SYK) Stock Forecast & Price Target

Stryker logo
$364.60 +7.46 (+2.09%)
(As of 05:30 PM ET)

Stryker - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
17

Based on 20 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 3 have given a hold rating, and 17 have given a buy rating for SYK.

Consensus Price Target

$405.80
11.30% Upside
According to the 20 analysts' twelve-month price targets for Stryker, the average price target is $405.80. The highest price target for SYK is $450.00, while the lowest price target for SYK is $360.00. The average price target represents a forecasted upside of 11.30% from the current price of $364.60.
Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

Sign Up

SYK Analyst Ratings Over Time

TypeCurrent Forecast
12/21/23 to 12/20/24
1 Month Ago
11/21/23 to 11/20/24
3 Months Ago
9/22/23 to 9/21/24
1 Year Ago
12/21/22 to 12/21/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
16 Buy rating(s)
15 Buy rating(s)
12 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$405.80$393.65$378.58$314.95
Forecasted Upside11.30% Upside2.07% Upside3.77% Upside6.39% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Stryker Stock vs. The Competition

TypeStrykerMedical CompaniesS&P 500
Consensus Rating Score
2.85
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside11.54% Upside25,271.08% Upside14.12% Upside
News Sentiment Rating
Positive News

See Recent SYK News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/18/2024Truist Financial
2 of 5 stars
 Boost TargetHold ➝ Hold$380.00 ➝ $409.00+11.04%
12/12/2024Needham & Company LLC
2 of 5 stars
 Boost TargetBuy ➝ Buy$409.00 ➝ $442.00+17.58%
12/11/2024Citigroup
3 of 5 stars
 Boost TargetBuy ➝ Buy$411.00 ➝ $450.00+19.39%
12/11/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$400.00 ➝ $425.00+11.51%
12/11/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$405.00 ➝ $427.00+11.66%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$370.00 ➝ $445.00+13.48%
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

10/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$402.00 ➝ $418.00+16.11%
10/30/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$383.00 ➝ $394.00+8.50%
10/30/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$360.00 ➝ $400.00+11.01%
10/30/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$380.00 ➝ $420.00+17.04%
10/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$375.00 ➝ $420.00+16.71%
10/30/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$366.00 ➝ $370.00+2.61%
10/30/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$380.00 ➝ $384.00+6.50%
10/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$378.00 ➝ $405.00+12.73%
9/10/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$405.00+11.64%
7/31/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$375.00 ➝ $365.00+11.86%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$372.00+9.06%
5/1/2024Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$348.00 ➝ $405.00+24.47%
4/11/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$365.00 ➝ $400.00+15.82%
9/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$310.00 ➝ $315.00+10.74%
5/25/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$285.00 ➝ $310.00+13.74%
5/2/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$260.00 ➝ $292.00-0.78%
5/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$320.00 ➝ $345.00+15.04%
4/23/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$275.00 ➝ $336.00+10.69%
4/17/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$290.00 ➝ $312.00+6.94%
1/25/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Weight ➝ Sector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:58 PM ET.


Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Stryker Co.:

  • Stryker Co. recently reported earnings per share (EPS) of $2.87, exceeding analysts' expectations of $2.77, indicating strong financial performance and effective management.
  • The company has shown a year-over-year revenue increase of 11.9%, reaching $5.49 billion, which reflects robust growth and demand for its medical technology products.
  • With a current stock price around $370.18, Stryker Co. is positioned well within its 52-week range, suggesting potential for appreciation as it approaches its 52-week high of $398.20.
  • Stryker Co. has a solid dividend yield of 0.88%, which can provide investors with a steady income stream, especially appealing in a low-interest-rate environment.
  • The company maintains a healthy debt-to-equity ratio of 0.66, indicating a balanced approach to leveraging debt for growth while minimizing financial risk.

Stryker
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Stryker Co. for these reasons:

  • The stock has a relatively high price-to-earnings (P/E) ratio of 41.77, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • Despite recent growth, the company's beta of 0.94 indicates that it is less volatile than the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • The dividend payout ratio (DPR) is at 34.30%, which, while sustainable, may limit the company's ability to reinvest profits into growth initiatives.
  • Analysts have mixed ratings, with four holding and seventeen giving buy ratings, indicating some uncertainty in market sentiment regarding the stock's future performance.
  • Recent target price adjustments by analysts suggest a cautious outlook, with some raising their targets but still reflecting a range that may not excite aggressive investors.

SYK Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $405.80, with a high forecast of $450.00 and a low forecast of $360.00.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SYK shares.

According to analysts, Stryker's stock has a predicted upside of 11.30% based on their 12-month stock forecasts.

Over the previous 90 days, Stryker's stock had 1 upgrade by analysts.

Analysts like Stryker more than other "medical" companies. The consensus rating score for Stryker is 2.85 while the average consensus rating score for "medical" companies is 2.81. Learn more on how SYK compares to other companies.


This page (NYSE:SYK) was last updated on 12/20/2024 by MarketBeat.com Staff
From Our Partners